Tools and Technologies I
ICOC Funds Committed:
Human stem cells hold great potential for use in stem cell-based therapies and regenerative medicine. Technologies developed to date, however, cannot create patient-specific embryonic cell lines, hence transplanting these cells poses innumerable immunological barriers. Another obstacle for embryonic stem cell use is their ability to form tumors. Human placenta is a potential source of primitive fetal stem cells, yet poorly studied. Large volumes of placental tissue could provide abundant numbers of primary stem cells, which will eliminate lengthy ex vivo stem cell propagation. In order to create placental banks, which will allow preservation of each individual’s placental stem cells, technology for the whole placenta cryopreservation ought to be developed. Our hypothesis is that the tissue of human term placenta is a high capacity source of primitive stem cells capable to differentiate into tissues of human body and placenta cryopreservation at birth will provide a life-long supply of own stem cells. In this project, we will demonstrate capability to cryopreserve placentas by means of perfusion with cryopreservation solutions. We will obtain cells from cryopreserved placental tissues and isolate cells expressing surface markers of human stem cells. Cells will be characterized by their morphology, ability to propagate long-term in culture, expression of human embryonic cell-specific markers, engraftment in immunocompromised mice. Use of placental stem cells will greatly reduce the need for embryonic stem cells, which cannot be obtained without destroying human pre-implantation embryos. Placenta as a source of abundant numbers of stem cells will eliminate the need for stem cell line propagation. Cryopreservation of individual placentas would provide life-long source of personal stem cells. As the aims of the application are achieved, creation of the novel placenta stem cell-based therapies will follow.
Statement of Benefit to California:
Stem cell-based therapies are the promising future of medicine. The application of this treatment is limited because of the restricted supply of appropriate stem cell lines, as it is necessary to match certain characteristics of the donor’s and host’s immune systems. Our pioneering studies demonstrated that human placenta may be used as a source of such stem cell lines. These cell lines derived from human placenta will contribute to research in stem cell biology and clinical applications. Furthermore, placentas are readily available from any individual giving birth. In order to create placental banks, which will allow preservation of each individual’s placental stem cells, technology for the whole placenta cryopreservation ought to be developed. Our hypothesis is that the tissue of human term placenta is a high capacity source of primitive stem cells capable to differentiate into tissues of human body, and placenta cryopreservation at birth will provide a life-long supply of own stem cells. As this approach does not require the donation or use of either human embryos or eggs, it will greatly reduce the ethical concerns, and may help overcome the limitations inherent in obtaining excess human embryos. Diseases that can potentially be cured by the use of stem cell treatment afflict significant number of individuals in California. These stem cell lines will be used in regenerative medicine research and cell replacement therapies as well as the development of new treatment approaches. The enhanced and extended lives of the individuals will represent an evident benefit; the savings to the health care system as a consequence of their cure will straightforwardly benefit all California taxpayers. Ultimately the knowledge and experience produced by the work proposed will contribute to the goal of making stem cell transplantation and new medical approaches available to a much broader group of patients, thus greatly extending the benefits to the affected individuals and to the taxpayers of California. Creation of placental banks and cryostorage of human placentas as a source of patient-specific stem cells throughout the life of each individual will some day become a medical necessity, and California may become the pioneer in this breakthrough initiative.